Catalyst Pharmaceuticals, Inc.
US ˙ NASDAQCM ˙ US14888U1016 ˙ Medical Devices
DIESES SYMBOL IST NICHT MEHR AKTIV

SecurityCPRX / Catalyst Pharmaceuticals, Inc.
InstitutionBLACKROCK FUNDS - iShares Total U.S. Stock Market Index Fund Investor A
Latest Disclosed Ownership7,096 shares
Latest Disclosed Value $ 199,610
BLACKROCK FUNDS - iShares Total U.S. Stock Market Index Fund Investor A ownership in CPRX / Catalyst Pharmaceuticals, Inc.

On June 25, 2026 - BLACKROCK FUNDS - iShares Total U.S. Stock Market Index Fund Investor A filed a NPORT-P form disclosing ownership of 7,096 shares of Catalyst Pharmaceuticals, Inc. (US:CPRX) valued at $199,610 USD as of April 30, 2026. The entity filed a previous NPORT-P on March 26, 2026 disclosing 7,096 shares of Catalyst Pharmaceuticals, Inc.. This represents a change in shares of 0.00% during the quarter. The current value of the position is $223,453 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-06-25 2026-04-30 NP Catalyst Pharmaceuticals EC US14888U1016 7,096 0 0.00 200 15.70 0.0044
2026-03-26 2026-01-31 NP Catalyst Pharmaceuticals EC US14888U1016 7,096 -1,796 -20.20 172 -8.99 0.0040
2025-12-29 2025-10-31 NP Catalyst Pharmaceuticals EC US14888U1016 8,892 0 0.00 189 0.00 0.0043
2025-09-24 2025-07-31 NP Catalyst Pharmaceuticals EC US14888U1016 8,892 0 0.00 190 -12.09 0.0046
2025-06-26 2025-04-30 NP Catalyst Pharmaceuticals EC US14888U1016 8,892 2,429 37.58 216 48.28 0.0059
2025-03-27 2025-01-31 NP Catalyst Pharmaceuticals EC US14888U1016 6,463 0 0.00 146 3.57 0.0037
2024-12-26 2024-10-31 NP Catalyst Pharmaceuticals EC US14888U1016 6,463 0 0.00 141 26.13 0.0038
2024-09-27 2024-07-31 NP Catalyst Pharmaceuticals EC US14888U1016 6,463 0 0.00 111 14.43 0.0031
2024-06-27 2024-04-30 NP Catalyst Pharmaceuticals EC US14888U1016 6,463 -338 -4.97 97 0.00 0.0031
2024-03-27 2024-01-31 NP Catalyst Pharmaceuticals EC US14888U1016 6,801 0 0.00 98 15.48 0.0033
2023-12-27 2023-10-31 NP Catalyst Pharmaceuticals EC US14888U1016 6,801 0 0.00 84 -10.64 0.0033
2023-09-26 2023-07-31 NP Catalyst Pharmaceuticals EC US14888U1016 6,801 -113 -1.63 94 -14.55 0.0033
2023-06-27 2023-04-30 NP Catalyst Pharmaceuticals EC US14888U1016 6,914 0 0.00 110 2.80 0.0042
2023-03-29 2023-01-31 NP Catalyst Pharmaceuticals EC US14888U1016 6,914 0 0.00 107 12.63 0.0039
2022-12-27 2022-10-31 NP Catalyst Pharmaceuticals EC US14888U1016 6,914 -129 -1.83 96 31.94 0.0038
2022-09-27 2022-07-31 NP Catalyst Pharmaceuticals EC US14888U1016 7,043 0 0.00 72 35.85 0.0029
2022-06-27 2022-04-30 NP Catalyst Pharmaceuticals EC US14888U1016 7,043 0 0.00 54 32.50 0.0023
2022-03-29 2022-01-31 NP Catalyst Pharmaceuticals EC US14888U1016 7,043 0 0.00 41 -2.44 0.0016
2021-12-28 2021-10-31 NP Catalyst Pharmaceuticals EC US14888U1016 7,043 4,091 138.58 42 141.18 0.0015
2021-09-28 2021-07-31 NP Catalyst Pharmaceuticals EC US14888U1016 2,952 0 0.00 17 30.77 0.0007
2021-06-28 2021-04-30 NP Catalyst Pharmaceuticals EC US14888U1016 2,952 0 0.00 14 30.00 0.0006
2021-03-31 2021-01-31 NP Catalyst Pharmaceuticals EC US14888U1016 2,952 0 0.00 11 25.00 0.0007
2020-12-28 2020-10-31 NP Catalyst Pharmaceuticals EC US14888U1016 2,952 0 0.00 9 -33.33 0.0007
2020-09-28 2020-07-31 NP Catalyst Pharmaceuticals EC US14888U1016 2,952 0 0.00 13 0.00 0.0010
2020-03-27 2020-01-31 NP Catalyst Pharmaceuticals EC US14888U1016 2,952 0 0.00 12 -7.69 0.0011
2019-12-26 2019-10-31 NP Catalyst Pharmaceuticals EC US14888U1016 2,952 2,952 14 0.0013
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.